The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas

Blood Cancer Journal

Volumn 4, Issue 5, 2014, Pages

  Briski, R ^a   Feldman, A L ^b   Bailey, N G ^a   Lim, M S ^a   Ristow, K ^b   Habermann, T M ^b   Macon, W R ^b   Inwards, D J ^b   Colgan, J P ^b   Nowakowski, G S ^b   Kaminski, M S ^a   Witzig, T E ^b   Ansell, S M ^b   Wilcox, R A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PERIPHERAL T CELL LYMPHOMA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; ADOLESCENT; AGED; COHORT ANALYSIS; DISEASE FREE SURVIVAL; LYMPHOMA, T-CELL, PERIPHERAL; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84901988214     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.34     Document Type: Article

References (34)

1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-4130.
2. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
4. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467-1475.
5. Reiser M, Josting A, Soltani M, Staib P, Salzberger B, Diehl V et al. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma 2002; 43: 805-811.
6. Torimoto Y, Sato K, Ikuta K, Hayashi T, Hirayama Y, Inamura J et al. A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group. Int J Hematol 2013; 98: 171-178.
7. Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005; 103: 2091-2098.
8. Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, Martinez A, Villamor N, Ghita G et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol 2011; 22: 397-404.
9. Chihara D, Oki Y, Ine S, Yamamoto K, Kato H, Taji H et al. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma 2009; 50: 1999-2004.
10. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011; 117: 3402-3408.
11. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474-2479.
12. Lee Y, Uhm JE, Lee HY, Park MJ, Kim H, Oh SJ et al. Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified". Ann Hematol 2009; 88: 111-119.
13. Asano N, Suzuki R, Kagami Y, Ishida F, Kitamura K, Fukutani H et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 2005; 29: 1284-1293.
14. Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo JM et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998; 9: 849-855.
15. Rudiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140-149.
16. Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, Hirano M. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol 2008; 26: 152-158.
17. Ascani S, Zinzani PL, Gherlinzoni F, Sabattini E, Briskomatis A, de Vivo A et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol 1997; 8: 583-592.
18. Pellatt J, Sweetenham J, Pickering RM, Brown L, Wilkins B. A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma. Ann Hematol 2002; 81: 267-272.
19. Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 2002; 38: 75-81.
20. Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005; 16: 206-214.
21. Arrowsmith ER, Macon WR, Kinney MC, Stein RS, Goodman SA, Morgan DS et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma 2003; 44: 241-249.
22. Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116: 3418-3425.
23. Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR et al. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and pre-dnisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma 2013; 54: 1373-1379.
24. Ganjoo K, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ et al. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 2013; 55: 768-772.
25. Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylpredni-solone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 2013; 119: 371-379.
26. Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012; 120: 2973-2980.
27. d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 3093-3099.
28. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012; 30: 631-636.
29. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29: 1182-1189.
30. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30: 2190-2196.
31. Zinzani PL, Pellegrini C, Broccoli A, Stefoni V, Gandolfi L, Quirini F et al. Lenali-domide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma 2011; 52: 1585-1588.
32. Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni F, Albertini P et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.[see comment]. Ann Oncol 1998; 9: 1351-1353.
33. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837-842.
34. Tobinai K, Takahashi T, Akinaga S. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Curr Hematol Malig Rep 2012; 7: 235-240.